-=Tyme Technologies (TYME) : metabolomic technology platform patent win

The patent, U.S. Patent No. 11,058,638, involves a targeted delivery of therapeutics to cancer cells.

The company was founded in 2014 and became publicly traded in 2015 when it executed a reverse merger into Global Group Enterprises and executed a private placement at $2.50 a share. 

Tyme Technologies: US Patent and Trademark Office granted additional patent claims related to the Company's metabolomic technology platform

• The patent, U.S. Patent No. 11,058,638, involves a targeted delivery of therapeutics to cancer cells.
• Tyme has developed a technology by which the tyrosine isomer racemetyrosine (a-methylparatyrosine) can be fused with a second therapeutic agent in a manner that creates a fusion compound that may allow targeted delivery to the cancer cells in a novel manner. This method of delivery, is predicated on the metabolic phenomenon in which cancer cells consume higher quantities of non-essential amino acids, including tyrosine, from their surrounding environment to support their growth because they cannot make enough of these amino acids.

Company Overview

0Tyme Technologies, Inc. (TYME) is a New York City based biotechnology company focused on developing cancer metabolism-based therapies (CMBTs) intended to be efficacious with relatively low toxicity profiles. The company was founded in 2014 and became publicly traded in 2015 when it executed a reverse merger into Global Group Enterprises and executed a private placement at $2.50 a share. Tyme is primarily owned by its two co-founders Steve Hoffman and Michael Demurjian, who between them control over 47% of the outstanding shares.